Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 108 recruiting now early-phase tilt #59 of 28,707 conditions

Endometrial Cancer: early-phase trial registry

108 of 188 indexed Endometrial Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #59 of 28,707 conditions by registered trial count.

188 US clinical trials · 108 currently recruiting · #59 of 28,707 conditions by registered trial count

Endometrial Cancer: 188 US clinical trials tracked, 108 recruiting.

Endometrial Cancer is the subject of 188 registered US clinical trials on ClinicalTrials.gov, 108 of them currently open to new participants. 15 are in Phase 3-4 (later-stage) and 118 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 17 of these trials.

Enrollment posture brief

Registry condition endometrial-cancer

OPEN 108 | RECR 57% | LATE 15 | EARLY 118 | RANK #59 | SPON 17

Nearest open-share peer: Mesothelioma (57% recruiting · 47 trials)

Advanced Solid Tumor70%Alcohol Use Disorder58.9%Endometrial Cancer (this)57%Chronic Lymphocytic Leukemia34.4%Smoking Cessation30.2%
Open-enrollment share among volume-matched conditions near Endometrial Cancer

Endometrial Cancer lists 108 open slots (57% of 188 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Endometrial Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Endometrial Cancer is recruiting above its size-band peers.

    108 of 188 indexed trials (57.4%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Endometrial Cancer trials is spread across many organizations.

    Memorial Sloan Kettering Cancer Center accounts for 17 of 188 trials (9%). 116 distinct sponsors appear on at least one study for this condition label.

  3. Typical Endometrial Cancer enrolment sits around 108 participants.

    Median target enrolment is 108 among the 182 trials that report a genuine target (sentinel values excluded). 85 of those (46.7%) plan for fewer than 100 participants.

  4. Endometrial Cancer research is mostly interventional.

    167 interventional and 21 observational studies make up this index (88.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 174Phase 244Phase 314Phase 41

Open and recent trials

188 total, page 4 of 4

COMPLETED NA 204 participants

Lymph Node Mapping in Patients With Endometrial Cancer

Ohio State University Comprehensive Cancer Center

NCT01818739

COMPLETED NA 180 participants

A Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping

Novadaq Technologies ULC, now a part of Stryker

NCT02209532

COMPLETED NA 155 participants

Scale Down for Endometrial Cancer

Washington University School of Medicine

NCT03169023

COMPLETED NA 151 participants

Intra-Operative Lymphatic Mapping in Patients With Invasive Carcinoma of the Cervix or Endometrial Carcinoma

Memorial Sloan Kettering Cancer Center

NCT00595725

COMPLETED Phase 1 149 participants

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

Incyte Corporation

NCT03314935

COMPLETED NA 111 participants

FitEx for Endometrial Cancer Survivors: Initial Efficacy

Carilion Clinic

NCT05737745

COMPLETED NA 106 participants

Non-Hormonal Vaginal Moisturizer in Hormone-Receptor Positive Postmenopausal Cancer Survivors Experiencing Estrogen Deprivation Symptoms on Vulvovaginal Health

Memorial Sloan Kettering Cancer Center

NCT01738152

COMPLETED 100 participants

Lymphedema in Endometrial Cancer

Duke University

NCT01914276

COMPLETED Phase 1 71 participants

Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.

Mundipharma Research Limited

NCT03345485

COMPLETED Phase 4 70 participants

A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment

Eli Lilly and Company

NCT00190697

COMPLETED Phase 2 70 participants

Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer

GlaxoSmithKline

NCT00267488

COMPLETED Phase 1 65 participants

Pelvic IMRT With Tomotherapy in Post-Hysterectomy Endometrial Cancer Patients

Washington University School of Medicine

NCT00334321

COMPLETED Phase 2 64 participants

SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma

Byondis B.V.

NCT04205630

COMPLETED Phase 2 53 participants

Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas

Memorial Sloan Kettering Cancer Center

NCT00474994

COMPLETED Phase 2 52 participants

Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer

National Cancer Institute (NCI)

NCT00033358

COMPLETED Phase 2 49 participants

Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium

University of Oklahoma

NCT03476798

COMPLETED Phase 1 48 participants

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Arcus Biosciences

NCT03629756

COMPLETED Phase 2 43 participants

A Study of Patients Receiving High-Dose Rate Brachytherapy

National Cancer Institute (NCI)

NCT00924027

COMPLETED Phase 2 38 participants

Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma

David O'Malley

NCT00513786

COMPLETED Phase 1 32 participants

Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

Santa Maria Biotherapeutics

NCT02262455

COMPLETED Phase 1 30 participants

Genistein in Preventing Breast or Endometrial Cancer in Healthy Postmenopausal Women

UNC Lineberger Comprehensive Cancer Center

NCT00099008

COMPLETED NA 25 participants

the Effectiveness of a Weight Management Program in Patients Who Have Completed Treatment for Endometrial Cancer

Sanford Health

NCT03908996

COMPLETED Early Phase 1 24 participants

A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium

UNC Lineberger Comprehensive Cancer Center

NCT02767362

COMPLETED Phase 1 24 participants

Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients

Dana-Farber Cancer Institute

NCT00268918

COMPLETED Phase 2 23 participants

A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus

NYU Langone Health

NCT02744898

COMPLETED Phase 2 22 participants

Trial of Maintenance With Niraparib- Uterine Serous Carcinoma

Northwell Health

NCT04080284

COMPLETED Phase 2 21 participants

Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer

M.D. Anderson Cancer Center

NCT00388154

COMPLETED Phase 2 21 participants

Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers

Dana-Farber Cancer Institute

NCT00545792

COMPLETED Early Phase 1 21 participants

Evaluation of the Molecular Effects of Metformin on the Endometrium in Patients With Endometrial Cancer

M.D. Anderson Cancer Center

NCT01205672

COMPLETED Phase 2 18 participants

CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer

Masonic Cancer Center, University of Minnesota

NCT00610740

COMPLETED Phase 1 15 participants

Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies

SCRI Development Innovations

NCT00315861

COMPLETED NA 15 participants

Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer

University of Wisconsin, Madison

NCT02096783

COMPLETED Phase 2

Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer

Gynecologic Oncology Group

NCT00005031

COMPLETED Phase 2

Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract

NYU Langone Health

NCT00003334

COMPLETED Phase 3

Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer

Radiation Therapy Oncology Group

NCT00006027

COMPLETED Phase 1

Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors

Beth Israel Deaconess Medical Center

NCT00004082

COMPLETED Phase 2

Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer

Memorial Sloan Kettering Cancer Center

NCT00006377

COMPLETED Phase 3

Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer

Gynecologic Oncology Group

NCT00002493

← Previous Page 4 of 4

Phase Distribution

PhaseTrial count
Phase 1 74
Phase 2 44
Phase 3 14
Phase 4 1

Named interventions

Most-linked intervention names on Endometrial Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Paclitaxel Drug
13 trials
Carboplatin Drug
10 trials
Pembrolizumab Drug
9 trials
Bevacizumab Drug
8 trials
Letrozole Drug
6 trials
Abemaciclib Drug
5 trials
Gemcitabine Drug
4 trials
Doxorubicin Drug
4 trials

US sites by state

Facility locations filed on Endometrial Cancer trials. A trial with sites in several states counts in each.

New York 72 trials
Texas 65 trials
California 63 trials
Florida 59 trials
Massachusetts 48 trials
Illinois 37 trials
New Jersey 36 trials
Ohio 35 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Endometrial Cancer page

188 registered trials, 108 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Endometrial Cancer condition card totals 188 registered trials; most-linked intervention Paclitaxel; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.